Skip to main content
. 2018 Sep 13;67(12):2494–2506. doi: 10.2337/db18-0474

Figure 7.

Figure 7

CETP inhibition with anacetrapib worsened insulin resistance in HFD-fed CETP mice. A: Euglycemia was maintained at ∼150 mg/dL during the clamp. B: GIR to maintain euglycemia was lower in anacetrapib-treated mice. C: Hepatic glucose production (Endo Ra) was less suppressed by insulin in anacetrapib-treated mice than in vehicle-treated mice. D: Rd was increased similarly for both groups by insulin during clamp. E and F: Insulin-mediated phosphorylation of liver AKT (473Ser) (pAKT473) was decreased in anacetrapib-treated mice shown by immunoblotting and its quantification. G–K: Liver content for TG, DG, NEFA, cholesterol, and phospholipids (PL). L: SBP for the third cohort of mice. CETP transgenic mice fed a chow diet were used as controls. Data are mean ± SD (n ≥ 6). Significant differences for A–D were determined using two-way ANOVA with Bonferroni multiple comparison test; statistical analyses for E–L were by Student t test. *P < 0.05, **P < 0.01, ***P < 0.001.